Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
Updates in Hodgkin’s and non-Hodgkin lymphomas
Dr Jose Sandoval-Sus - Moffitt Cancer Center, Tampa, USA
Updates in Hodgkin’s and non-Hodgkin lymphomas ( Dr Jose Sandoval-Sus - Moffitt Cancer Center, Tampa, USA )
30 Jul 2021
OncoAlert and ecancer weekly round up for July 19 - July 25, 2021
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
OncoAlert and ecancer weekly round up for July 19 - July 25, 2021 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )
26 Jul 2021
OncoAlert and ecancer weekly round up for July 1- July 10, 2021
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
OncoAlert and ecancer weekly round up for July 1- July 10, 2021 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )
13 Jul 2021
ZUMA-3: KTE-X19, an anti-CD19 chimeric antigen receptor T-cell therapy for R/R B...
Dr Bijal Shah - H. Lee Moffitt Cancer Center & Research Institute, Tampa, USA
ZUMA-3: KTE-X19, an anti-CD19 chimeric antigen receptor T-cell therapy for R/R B-cell acute lymphoblastic leukaemia ( Dr Bijal Shah - H. Lee Moffitt Cancer Center & Research Institute, Tampa, USA )
12 Jul 2021
Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethaso...
Prof Thierry Facon - Chu De Lille, Lille, France
Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed MM ( Prof Thierry Facon - Chu De Lille, Lille, France )
25 Jun 2021
The clinical value of maintenance in multiple myeloma
Prof Wee Joo Chng - National University of Singapore, Singapore
The clinical value of maintenance in multiple myeloma ( Prof Wee Joo Chng  - National University of Singapore, Singapore )
25 Jun 2021
Once weekly selinexor, carfilzomib, and dexamethasone (XKD) in carfilzomib non-r...
Prof Cristina Gasparetto - Duke Cancer Institute, Durham, USA
Once weekly selinexor, carfilzomib, and dexamethasone (XKD) in carfilzomib non-refractory multiple myeloma patients ( Prof Cristina Gasparetto - Duke Cancer Institute, Durham, USA )
25 Jun 2021
Isatuximab, carfilzomib, lenalidomide and dexamethasone for high risk MM
Prof Katja Weisel - University Medical Center Hamburg-Eppendorf, Hamburg, German...
Isatuximab, carfilzomib, lenalidomide and dexamethasone for high risk MM ( Prof Katja Weisel - University Medical Center Hamburg-Eppendorf, Hamburg, Germany )
25 Jun 2021
Carfilzomib-lenalidomide-dexamethasone in the management of lenalidomide-refract...
Dr Claudio Cerchione - IRCCS, Meldola, Italy
Carfilzomib-lenalidomide-dexamethasone in the management of lenalidomide-refractory multiple myeloma ( Dr Claudio Cerchione - IRCCS, Meldola, Italy )
23 Jun 2021
Dose-escalation of mosunetuzumab with polatuzumab vedotin for R/R B-cell non-Hod...
Dr Nilanjan Ghosh - Atrium Health Levine Cancer Institute, Charlotte, USA
Dose-escalation of mosunetuzumab with polatuzumab vedotin for R/R B-cell non-Hodgkin’s lymphoma ( Dr Nilanjan Ghosh - Atrium Health Levine Cancer Institute, Charlotte, USA )
22 Jun 2021
Efficacy and safety of tisagenlecleucel in adult patients with relapsed/refracto...
Dr Stephen Schuster - Perelman Center for Advanced Medicine, Philadelphia, USA
Efficacy and safety of tisagenlecleucel in adult patients with relapsed/refractory follicular lymphoma ( Dr Stephen Schuster - Perelman Center for Advanced Medicine, Philadelphia, USA )
21 Jun 2021
First results of a head-to-head trial of acalabrutinib versus ibrutinib in previ...
Dr John Byrd - The Ohio State University, Columbus, USA
First results of a head-to-head trial of acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukaemia ( Dr John Byrd - The Ohio State University, Columbus, USA )
21 Jun 2021